Tocilizumab Effective For Severe COVID-19 Cases

 

Rheumatoid arthritis drug tocilizumab has recently found to be effective in treating severe cases of COVID-19 however, other experts urged a caution until the full results is released for some are already confident of it and stop making trials of it.

“Preliminary trial data has suggested that tocilizumab may be effective in improving outcomes for patients severely affected by the SARS-CoV-2 virus; however, full results are still awaited.  On 20-11-2020 the word was spread that a worldwide survey had shown that tocilizumab may, in half of the severe covid-19 cases, lead to less death, shorter stay in hospitals (IC's) and less dependency on support of vital functions.”(Wikipedia)

“Tocilizumab (INN, trade name Actemra), also known as atlizumab, is an immunosuppressive drug, mainly for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis, a severe form of arthritis in children. It is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer.”(Wikipedia)

The main point : Tocilizumab an arthritis drug was discovered to help severe cases of COVID-19 ease the pain and the succumb to death.

image from Science News website